Phase 3 Alzheimer's drug increases toxic beta amyloid in the brain -- but still provides benefits

New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news166867134.html">Phase 3 Alzheimer's drug increases toxic beta amyloid in the brain -- but still provides benefits</a></p> <p>New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.</p>